NZ597866A - Therapeutic lactams - Google Patents

Therapeutic lactams

Info

Publication number
NZ597866A
NZ597866A NZ597866A NZ59786607A NZ597866A NZ 597866 A NZ597866 A NZ 597866A NZ 597866 A NZ597866 A NZ 597866A NZ 59786607 A NZ59786607 A NZ 59786607A NZ 597866 A NZ597866 A NZ 597866A
Authority
NZ
New Zealand
Prior art keywords
lactams
therapeutic
formula
glaucoma
mammal
Prior art date
Application number
NZ597866A
Other languages
English (en)
Inventor
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of NZ597866A publication Critical patent/NZ597866A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NZ597866A 2006-08-11 2007-08-09 Therapeutic lactams NZ597866A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82210806P 2006-08-11 2006-08-11

Publications (1)

Publication Number Publication Date
NZ597866A true NZ597866A (en) 2013-08-30

Family

ID=38683367

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ597866A NZ597866A (en) 2006-08-11 2007-08-09 Therapeutic lactams

Country Status (11)

Country Link
US (2) US7482475B2 (enExample)
EP (1) EP2066660A2 (enExample)
JP (1) JP2010500416A (enExample)
KR (1) KR101422305B1 (enExample)
CN (1) CN101522669B (enExample)
AU (1) AU2007286177B2 (enExample)
BR (1) BRPI0716742A2 (enExample)
CA (1) CA2660608A1 (enExample)
MX (1) MX2009001578A (enExample)
NZ (1) NZ597866A (enExample)
WO (1) WO2008021975A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) * 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
EP2066660A2 (en) * 2006-08-11 2009-06-10 Allergan, Inc. Therapeutic lactams
US7589213B2 (en) * 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US7820661B2 (en) * 2008-04-24 2010-10-26 Allergan, Inc. Substituted gamma lactams as therapeutics agents
WO2014031581A1 (en) * 2012-08-21 2014-02-27 Allergan, Inc. Process for the synthesis of substituted gamma lactams
US20150274658A1 (en) * 2014-03-27 2015-10-01 Allergan, Inc. Therapeutic lactams
US9745253B2 (en) 2015-03-13 2017-08-29 Forma Therapeutics, Inc. Alpha-cinnamide compounds and compositions as HDAC8 inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1991504A (en) * 1928-09-12 1935-02-19 American District Telegraph Co Key-trapping valve lock for transmitter-supervised sprinkler systems
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5902726A (en) * 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
AU2003211574A1 (en) * 2002-03-05 2003-09-16 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivative compounds and drugs containing the compounds as the active ingredient
JP2006504679A (ja) * 2002-08-28 2006-02-09 メルク フロスト カナダ アンド カンパニー 緑内障の治療においてep4受容体作動薬として使用するためのオキサゾリジン−2−オンおよびチアゾリジン−2−オン誘導体
WO2006061366A1 (en) * 2004-12-06 2006-06-15 Laboratoires Serono S.A. Pyrrolidin-2-one derivatives for use as dp1 receptor agonists
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2007226957B2 (en) * 2006-03-20 2013-08-15 Allergan, Inc. Substituted gamma lactams as prostaglandin EP2 agonists
EP2066660A2 (en) * 2006-08-11 2009-06-10 Allergan, Inc. Therapeutic lactams

Also Published As

Publication number Publication date
US20080039505A1 (en) 2008-02-14
AU2007286177A1 (en) 2008-02-21
US20090099249A1 (en) 2009-04-16
KR20090038937A (ko) 2009-04-21
CA2660608A1 (en) 2008-02-21
CN101522669B (zh) 2013-01-16
AU2007286177B2 (en) 2012-06-14
WO2008021975A3 (en) 2008-07-10
KR101422305B1 (ko) 2014-07-22
EP2066660A2 (en) 2009-06-10
MX2009001578A (es) 2009-02-19
US7482475B2 (en) 2009-01-27
CN101522669A (zh) 2009-09-02
US8686025B2 (en) 2014-04-01
WO2008021975A2 (en) 2008-02-21
BRPI0716742A2 (pt) 2015-03-24
JP2010500416A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
TW200728307A (en) Novel spirochromanone derivatives
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
WO2007136759A3 (en) Method for the treatment and prevention of ocular disorders
WO2010057101A3 (en) Compounds useful as hiv blockers
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MX2010008226A (es) Derivados de difluorobifenilamida para el tratamiento de hipertension ocular.
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2009003081A (es) Derivados de pirrola utiles para el tratamiento de enfermedades mediadas por citoquinas.
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
HK1215579A1 (zh) 被取代的2,3-二氫苯並呋喃基化合物和其用途
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
TW200736233A (en) Cyclohexyl piperazinyl methanone derivatives
NO20082096L (no) Azaindol-2-karboksamidderivativer
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
MX2011012122A (es) Derivados de tiofeno.
TW200740787A (en) (6-Fluoro-benzo[1,3]dioxolyl)-morpholin-4-yl-methanones
WO2009124962A3 (en) Sulfonamides
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
TW200626158A (en) Naphthaline derivatives
WO2009109501A3 (en) Ocular pharmaceutical compositions
TW200716547A (en) Piperidin-4-yl-amide derivatives

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1145891, OLD, DAVID W; 3072836, BURK, ROBERT M., 1337 CERRITOS AVENUE, LAGUNA BEACH, CALIFORNIA 92651, US)

Effective date: 20130820

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 AUG 2014 BY AJ PARK

Effective date: 20140401

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 AUG 2017 BY COMPUTER PACKAGES INC

Effective date: 20140828

LAPS Patent lapsed